US, Canada, Australia Approve Endometrial Cancer Combo US, Canada, Australia Approve Endometrial Cancer Combo

Regulatory agencies in three countries, including the United States, all approved lenvatinib in combination with pembrolizumab for the treatment of patients with advanced endometrial carcinoma.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Related Links:

Endometrial carcinoma has been traditionally divided into type 1 or endometrioid type that is usually moderate to well differentiated and type 2 that is usually poorly differentiated with high histologic grade and aggressive clinical behavior. However, interobserver diagnostic agreement is suboptimal, particularly among the high-grade histotypes. Furthermore, recent data indicate that this histotype assignment does not independently correlate with survival. In recent years, there has been remarkable progress in our understanding of the molecular basis of endometrial carcinoma and extensive molecular studies have been perfo...
Source: Advances in Anatomic Pathology - Category: Pathology Tags: Review Articles Source Type: research
Endometrial cancer is a common disease, and in England all cancer cases are discussed at a central multidisciplinary meeting (MDT) with pathology review. We reviewed cases discussed/reviewed at a regional Gynecology MDT comparing (i) original referral histology with review histology and (ii) final review histology with the final hysterectomy histology. Cases identified as potentially eligible for the study (n=884) were found over a 4-yr period. This was reduced to 630 due to data and other issues for the primary biopsy review, and to 488 for both biopsy and hysterectomy sample. Cases were classed by agreement by grade/type...
Source: International Journal of Gynecological Pathology - Category: Pathology Tags: Pathology of the Corpus: Original Articles Source Type: research
Primary mucinous carcinoma of the ovary is uncommon, and while numerous studies have focused on improving our ability to distinguish these tumors from gastrointestinal metastases, recent data suggest that up to one fifth are still misdiagnosed with a previously underrecognized culprit: endometrioid carcinoma. Using an index case of an ovarian endometrioid carcinoma with mucinous differentiation masquerading as a mucinous carcinoma, we sought to identify the most efficient biomarker combination that could distinguish these 2 histotypes. Eight immunohistochemical markers were assessed on tissue microarrays from 183 endometri...
Source: International Journal of Gynecological Pathology - Category: Pathology Tags: Pathology of the Upper Tract: Original Articles Source Type: research
Condition:   Endometrial Cancer Intervention:   Procedure: hysterectomy Sponsor:   Assiut University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 5 October 2019Source: Gynecologic Oncology ReportsAuthor(s): Jennifer McEachron, Rachel Mendoza, Yi-Chun Lee, Margaux J. KanisAbstractMetastasis of non-mammary tumors to the breast are uncommon, representing
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
Authors: Li HL, Sun JJ, Ma H, Liu SJ, Li N, Guo SJ, Shi Y, Xu YY, Qi ZY, Wang YQ, Wang F, Guo RM, Liu D, Xue FX Abstract The present study focused on exploring the inhibitory mechanism of microRNA (miR)-23a in endometrial cancer. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was used to investigate miR-23a expression in endometrial tissues and endometrial cancer cells. A colony formation assay using crystal violet staining was performed to compare cell proliferation, while wound-healing and Transwell assays were performed to compare cell migration and invasion. Subsequently, bioinformatics ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Abnormal uterine bleeding around the time of the menopause is common and may be a sign of premalignancy such as endometrial hyperplasia or even endometrial carcinoma. All such women therefore need uterine assessment, which may include transvaginal scan combined with endometrial biopsy, hysteroscopy or a sonohysterogram. Having excluded (pre) cancer, treatment can then be offered. Medical treatment options include tranexamic acid to reduce blood loss, low-dose contraceptive pills, the levonorgestrel intra-uterine device and cyclic progestins.
Source: Obstetrics, Gynaecology and Reproductive Medicine - Category: OBGYN Authors: Tags: Case-based learning Source Type: research
Diagnosis of endometrial carcinoma made easier by analysis of mutations in cervix or endometrial tissue.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Conclusions: In summary, detection of DNA MMR deficiencies by IHC can effectively diagnose the MSI phenotype in endometrial carcinoma. Correlation between clinicopathologic parameters showed MMR deficiency was significantly associated with low-grade tumor and localized stage.
Source: Applied Immunohistochemistry and Molecular Morphology - Category: Chemistry Tags: Research Articles Source Type: research
This study investigated the prevalence and the distribution of FGFR aberrations in Chinese cancer patients.MethodsWe screened genomic profiling results of plasma or tissue samples from 10,582 patients spanning 16 cancer types: lung, breast, gastric, hepatobiliary, pancreatic, soft tissue sarcoma, esophageal, ovarian, colorectal, head and neck, renal, endometrial, osteogenic sarcoma, cervical, melanoma and lymphoma.ResultsOf the 10,582 patients screened, we observed 745 patients with FGFR aberrations, revealing an overall prevalence of 7.03%. Approximately, 3.78% harbored FGFR amplification, 2.73% had other mutations and 0....
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Australia Health | Canada Health | Cancer | Cancer & Oncology | Carcinoma | Endometrial Cancer | Health | Hematology | USA Health